Side effects of methotrexate treatment in patients with rheumatoid arthritis

Advances in Clinical and Experimental Medicine

Volumn 17, Issue 4, 2008, Pages 387-394

  Świerkot, Jerzy ^a,b   Szechiński, Jacek ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b NONE   (Poland)

Author keywords

Methotrexate; Polyarteritis rheumatoidea; Toxicity

Indexed keywords

EID: 54749133022     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF: The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology 2005, 44, 61-66.
2. Swierkot J, Szechiński J, Wiland P: Piȩcioletnia ocena kliniczna skuteczności leczenia metotreksatem chorych na reumatoidalne zapalenie stawów. Pol Arch Med Wewn 2000, 103, 267-275.
3. Wluka A, Buchbinder R, Mylvaganam: Long term methotrexate use in rheumatoid arthritis: 12 year follow up of 460 patients treated in community practice. J Rheumatol 2000, 27, 1864-1871.
4. Suarez-Almazor ME, Soskolne CL, Saunders LD: Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. J Rheumatol 1995, 22, 836-843.
5. Wolfe F, Hawley DJ, Cathey MA: Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990, 17, 994-1002.
6. Kremer JM: Toward a better understanding of methotrexate. Arthritis Rheum 2004, 50(5), 1370-1382.
7. Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijsen MW, Laan RF: Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62(5), 423-426.
8. Cooper BA: Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med 1996, 124, 73; author reply 74.
9. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcon GS: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990, 33(1), 9-18.
10. Lederle: Summarized data of the controlled multicenter studies of Ward and Weinblatt, In: Methotrexate - Rheumatoid Arthritis - Expanded Clinical Summary. New York 1985.
11. Fathi NH, Mitros F, Hoffman J, Straniero N, Labreque D, Koehnke R, Furst DE: Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J Rheumatol 2002, 29(10), 2092-2098.
12. Veen MJ, Dekker JJ, Dinant HJ, Soesbergen RM: Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. J Rheumatol 1995, 22, 1766-1768.
13. Anaya JM, Diethelm L, Ortiz LA, Gutierrez M, Citera G, Welsh RA, Espinoza LR: Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995, 24, 242-254.
14. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP: Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology 2002, 41, 262-267.
15. Khadadah ME, Jayakrishnan B, Al-Gorair S, Al-Mutairi M, Al-Maradni N, Onadeko B, Malaviya AN: Effect of methotrexate on pulmonary function in patients with rheumatoid arthritis - a prospective study. Rheumatol Int 2002, 22, 204-207.
16. Miyata M, Sakuma F, Fukaya E, Kobayashi H, Rai T, Saito H, Kasukawa R, Suzuki S: Detection and monitoring of methotrexate-associated lung injury using serum markers KL-6 and SP-D in rheumatoid arthritis. Intern Med 2002, 41, 467-473.
17. Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR: Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996, 39, 272-276.
18. Kuitunen T, Malmstrom J, Palva E, Pettersson T: Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999. Scand J Rheumatol 2005, 34, 238-241.
19. Schnabel A, Gross WL: Low-dose methotrexate in rheumatic diseases - efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994, 23,5, 310-327.
20. Ebeo CT, Grish MR, Byrd RP, Roy TM, Mehta JB: Methotrexate-induced pulmonary lymphoma. Chest 2003, 123, 2150-2153.
21. Halla JT, Hardin JG: Under-recognized postdosing reactions to methotrexate in patients with rheumatoid arthritis. J Rheumatol 1994, 21, 1224-1226.
22. Weinblatt ME: Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl 1985, 12, 35-39.
23. Combe B, Guttierrez M, Anaya JM, Sany J: Possible efficacy of hydroxychloroquine on accelerated nodulosis during methotrexate therapy for rheumatoid arthritis. J Rheumatol 1993, 20, 755-756.
24. Merrill JT, Cronstein BN, Shen C: Reversal of new but not old rheumatoid nodules by colchicine: Evidence from an in vitro model and case reports of 14 patients. Arthritis Rheum (Suppl) 1996 [Abstract 7] 84.
25. Bannwarth B, Labat L, Moride Y: Methotrexate in rheumatoid arthritis. Drugs 1994, 47, 25-50.